FRESENIUS MEDICAL CARE AG vs PACS Group, Inc., two Medical Care stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
PACS earns 23.4% on equity against Fresenius Medical's 8.3%, skilled nursing out-returning global dialysis by a factor the scale gap cannot explain, $7B against $14B. The margin lines are closer, 8.5% and 11.7% operating, so the return gap is asset intensity: dialysis clinics and machines against leased nursing facilities. The multiples price the smaller returner dearer, 27 times earnings against 12.7. Fresenius' rebuttal is cash and yield, a 21.5% free-cash figure and 1.7% dividend against 7.2% and 0.5%. Both sheets are conservative. High returns at a high price against modest returns at a low one; the pair is the sector's cleanest value-versus-quality standoff.
Comparison updated 2026-07-10.
| Metric | FMS | PACS |
|---|---|---|
| Price | $23.25 | $41.88 |
| Market cap | $13.6B | $6.8B |
| Sector | Medical Care | Medical Care |
| Stage | Mature | Growth |
| Implied growth (priced in) | — | +7.9% |
| P/E | 12.7 | 27.0 |
| P/B | 0.87 | 6.51 |
| P/S | 0.64 | 1.25 |
| EV/EBITDA | 3.3 | 17.8 |
| Revenue growth | +1.5% | +23.6% |
| Operating margin | 11.7% | 8.4% |
| Net margin | 6.1% | 4.5% |
| Return on equity | 8.3% | 23.4% |
| Return on assets | 3.8% | 4.3% |
| Return on invested capital | 10.1% | 21.0% |
| FCF yield | 21.4% | 7.2% |
| Dividend yield | 1.7% | 0.5% |
| Debt / equity | 0.00 | 0.24 |
| Current ratio | 1.26 | 0.99 |
| Altman Z (solvency) | 1.76 | 2.01 |
| Piotroski F (quality) | 8 / 9 | 7 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.